ACAD
32.14
-0.26
-0.80%
AEMD
4.92
+0.1
+2.0726%
APRI
0.54
-0.002
-0.3875%
ARNA
1.745
-0.025
-1.412%
ATEC
0.24
0.00
+0.71%
CNAT
2.85
0.00
0.00%
CRXM
0.19
0.00
0.00%
CYTX
0.312
-0.028
-8.1176%
DXCM
63.99
-1.97
-2.99%
GNMK
5.86
-0.21
-3.46%
HALO
10.535
-0.305
-2.814%
ILMN
132.87
-2.88
-2.12%
INNV
0.09
-0.01
-6.25%
INO
10.335
-0.845
-7.558%
ISCO
3.8
-0.05
-1.30%
ISIS
57.56
0.00
0.00%
LGND
121.07
-2.05
-1.67%
LPTN
0.23
-0.012
-4.9153%
MBVX
0.685
-0.04
-5.491%
MEIP
1.41
+0.01
+0.71%
MNOV
6.79
-0.19
-2.72%
MRTX
20.78
-0.26
-1.24%
MSTX
0.298
-0.003
-0.8973%
NBIX
45.47
-1.43
-3.05%
NUVA
52.73
-0.37
-0.70%
ONCS
1.93
-0.02
-1.03%
ONVO
2.693
-0.057
-2.0655%
OREX
0.45
-0.016
-3.4934%
OTIC
14.215
-0.405
-2.770%
QDEL
17.23
-0.45
-2.55%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.51
-0.99
-1.75%
SPHS
1.19
-0.01
-0.83%
SRNE
6.69
-0.21
-3.04%
TROV
3.922
-0.239
-5.7332%
VICL
0.384
-0.011
-2.8861%
VOLC
18
0.00
0.00%
ZGNX
10.19
-0.44
-4.14%
ACAD
32.14
-0.26
-0.80%
AEMD
4.92
+0.1
+2.0726%
APRI
0.54
-0.002
-0.3875%
ARNA
1.745
-0.025
-1.412%
ATEC
0.24
0.00
+0.71%
CNAT
2.85
0.00
0.00%
CRXM
0.19
0.00
0.00%
CYTX
0.312
-0.028
-8.1176%
DXCM
63.99
-1.97
-2.99%
GNMK
5.86
-0.21
-3.46%
HALO
10.535
-0.305
-2.814%
ILMN
132.87
-2.88
-2.12%
INNV
0.09
-0.01
-6.25%
INO
10.335
-0.845
-7.558%
ISCO
3.8
-0.05
-1.30%
ISIS
57.56
0.00
0.00%
LGND
121.07
-2.05
-1.67%
LPTN
0.23
-0.012
-4.9153%
MBVX
0.685
-0.04
-5.491%
MEIP
1.41
+0.01
+0.71%
MNOV
6.79
-0.19
-2.72%
MRTX
20.78
-0.26
-1.24%
MSTX
0.298
-0.003
-0.8973%
NBIX
45.47
-1.43
-3.05%
NUVA
52.73
-0.37
-0.70%
ONCS
1.93
-0.02
-1.03%
ONVO
2.693
-0.057
-2.0655%
OREX
0.45
-0.016
-3.4934%
OTIC
14.215
-0.405
-2.770%
QDEL
17.23
-0.45
-2.55%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.51
-0.99
-1.75%
SPHS
1.19
-0.01
-0.83%
SRNE
6.69
-0.21
-3.04%
TROV
3.922
-0.239
-5.7332%
VICL
0.384
-0.011
-2.8861%
VOLC
18
0.00
0.00%
ZGNX
10.19
-0.44
-4.14%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.